0.7341

1.32% -0.0098

After Hours: .73 -0.0041 -0.56%

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $0.7341, with a volume of 259.12K. It is down -1.32% in the last 24 hours and up +5.93% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Previous Close:

$0.7439

Open:

$0.7436

24h Volume:

259.12K

Relative Volume:

0.25

Market Cap:

$35.89M

Revenue:

Net Income/Loss:

$-81.22M

P/E Ratio:

-0.248

EPS:

-2.96

Net Cash Flow:

$-74.41M

1W Performance:

+5.17%

1M Performance:

+5.93%

6M Performance:

-33.26%

1Y Performance:

-26.58%

1-Day Range:

$0.714

$0.7436

1-Week Range:

$0.6818

$0.745

52-Week Range:

$0.62

$1.70

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (655)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-09

Latest SEC Filings

XLO's Discussions on Twitter

Compare XLO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XLO Xilio Therapeutics Inc	0.7341	35.89M	0	-81.22M	-74.41M	-2.96
VRTX Vertex Pharmaceuticals Inc	468.85	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	567.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	314.94	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	560.24	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	250.30	28.51B	3.81B	-644.79M	-669.77M	-6.24

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

Jun 18, 2025

Xilio Therapeutics appoints oncology veteran Akintunde Bello to board By Investing.com - Investing.com South Africa

Jun 10, 2025

Xilio Therapeutics expands board, elects new director - Investing.com Australia

Jun 10, 2025

Xilio Therapeutics expands board, elects new director By Investing.com - Investing.com South Africa

Jun 10, 2025

Xilio Therapeutics Expands Board with New Director - TipRanks

Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Manila Times

Jun 10, 2025

Xilio Therapeutics appoints oncology veteran Akintunde Bello to board - Investing.com

Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., To Its Board Of Directors - MarketScreener

Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors - Nasdaq

Jun 10, 2025

Bristol Myers Squibb Oncology Leader Joins Xilio Board: Key Boost for Novel Cancer Immunotherapy Programs - Stock Titan

Jun 10, 2025

Leadership Experience 2025: Starbucks Rallies 14,000 North America Coffeehouse Leaders to Accelerate its 'Back to Starbucks' Strategy - The Globe and Mail

Jun 10, 2025

Jun 08, 2025

Uranium Royalty Corp. Announces U.S.$30 Million Bought Deal Financing - The Globe and Mail

Jun 08, 2025

Jun 06, 2025

Musk-Trump Messy Breakup Wipes Out $150B in TSLA Stock: What's Next? - The Globe and Mail

Jun 06, 2025

Jun 05, 2025

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire

Jun 05, 2025

Xilio Therapeutics Announces $50 Million Public Offering and Potential $150 Million in Total Gross Proceeds - Nasdaq

Jun 05, 2025

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire Inc.

Jun 05, 2025

Jun 04, 2025

Market Analysis: June 4th, 2025 - The Globe and Mail

Jun 04, 2025

Jun 03, 2025

International Resources Holding Enters into Agreement to Acquire Majority Interest in Alphamin Resources Corp. from Tremont Master Holdings - The Globe and Mail

Jun 03, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 03, 2025

Biotech Startup Xilio Awards $194K Worth of Stock Options Under Nasdaq Compliance Plan - Stock Titan

Jun 03, 2025

Xilio Therapeutics Inc (NASDAQ: XLO) Is Down -26.69% Year-To-Date, But Analysts Find Room For A Price Rally - Stocksregister

Jun 03, 2025

Form 424B5 Xilio Therapeutics, Inc. - StreetInsider

Jun 03, 2025

Xilio Therapeutics announces public offering of warrants By Investing.com - Investing.com South Africa

Jun 03, 2025

Jun 02, 2025